The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Multi-Target-Directed Drug Design Strategy: From a Dual Binding Site Acetylcholinesterase Inhibitor to a Trifunctional Compound against Alzheimer’s Disease
Open accessAbstract
A design strategy to convert a dual-binding site AChE inhibitor into triple functional compounds with promising in vitro profile against multifactorial syndromes, such as Alzheimer's disease, is proposed. The lead compound bis(7)-tacrine (2) was properly modified to confer to the new molecules the ability of chelating metals, involved in the neurodegenerative process. The multifunctional compounds show activity against human AChE, are able to inhibit the AChE-induced amyloid-beta aggregation, and chelate metals, such as iron and copper.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
A Century of Alzheimer's Disease
Goedert, M., & Spillantini, M. G. (2006) · Science · doi:10.1126/science.1132814 · Cited by 2,098
Gaggelli, E., Kozlowski, H., Valensin, D., & Valensin, G. (2006) · Chemical Reviews · doi:10.1021/cr040410w · Cited by 1,729
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159
From magic bullets to designed multiple ligands
Morphy, R., Kay, C., & Rankovic, Z. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03163-0 · Cited by 729
β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies
Bartolini, M., Bertucci, C., Cavrini, V., & Andrisano, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01514-9 · Cited by 568
Self-citation100 Years and Counting: Prospects for Defeating Alzheimer's Disease
Roberson, E. D., & Mucke, L. (2006) · Science · doi:10.1126/science.1132813 · Cited by 550
Baum, L., & Ng, A. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6403 · Cited by 483
Can we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy
Gaeta, A., & Hider, R. C. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706416 · Cited by 411
Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders
Youdim, M. B. H., & Buccafusco, J. J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.11.007 · Cited by 380
Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase
Pang, Y.-P., Quiram, P., Jelacic, T., Hong, F., & Brimijoin, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23646 · Cited by 344
Targeting acetylcholinesterase to treat neurodegeneration
Holzgrabe, U., Kapková, P., Alptüzün, V., Scheiber, J., & Kugelmann, E. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.161 · Cited by 217
Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors
Castro, A., & Martinez, A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778792985 · Cited by 207
The Physicochemical Challenges of Designing Multiple Ligands
Morphy, R., & Rankovic, Z. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603015 · Cited by 194
Rydberg, E. H., Brumshtein, B., Greenblatt, H. M., Wong, D. M., Shaya, D., Williams, L. D., Carlier, P. R., Pang, Y.-P., Silman, I., & Sussman, J. L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060164b · Cited by 190
A Small Molecule Targeting the Multifactorial Nature of Alzheimer's Disease
Cavalli, A., Bolognesi, M. L., Capsoni, S., Andrisano, V., Bartolini, M., Margotti, E., Cattaneo, A., Recanatini, M., & Melchiorre, C. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700256 · Cited by 179
Self-citationMetals in our minds: therapeutic implications for neurodegenerative disorders
Doraiswamy, P. M., & Finefrock, A. E. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00809-9 · Cited by 161
One‐compound‐multiple‐targets strategy to combat Alzheimer's disease
Zhang, H. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.09.006 · Cited by 140
Carlier, P. R., Chow, E. S. ‐., Han, Y., Liu, J., Yazal, J. E., & Pang, Y. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990224w · Cited by 129
Dimeric and Hybrid Anti-Alzheimer Drug Candidates
Munoz-Torrero, D., & Camps, P. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706775527974 · Cited by 107
Homodimeric Tacrine Congeners as Acetylcholinesterase Inhibitors
Hu, M., Wu, L.-J., Hsiao, G., & Yen, M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010308g · Cited by 104
Du, D., & Carlier, P. R. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383412 · Cited by 71
Acetylcholinesterase Inhibitors as a Starting Point Towards Improved Alzheimers Disease Therapeutics
Recanatini, M., & Valenti, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383313 · Cited by 66
Self-citationCappelli, A., Gallelli, A., Manini, M., Anzini, M., Mennuni, L., Makovec, F., Menziani, M. C., Alcaro, S., Ortuso, F., & Vomero, S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493461 · Cited by 62
Effects of bis(7)-tacrine, a novel anti-Alzheimerʼs agent, on rat brain AChE
Wang, H., Carlier, P. R., Ho, W. L., Wu, D., Lee, N. T. K., Li, C. P. L., Pang, Y., & Han, Y. (1999) · Neuroreport · doi:10.1097/00001756-199903170-00023 · Cited by 60
Felder, C. E., Harel, M., Silman, I., et al. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902011642 · Cited by 43
Small, D. H. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.4.817 · Cited by 39
Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors
Bolognesi, M. L., Cavalli, A., Andrisano, V., Bartolini, M., Banzi, R., Antonello, A., Rosini, M., & Melchiorre, C. (2003) · Il Farmaco · doi:10.1016/s0014-827x(03)00150-2 · Cited by 13
Self-citation
Cited by
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Advantages and limitations of common testing methods for antioxidants
Amorati, R., & Valgimigli, L. (2015) · Free Radical Research · doi:10.3109/10715762.2014.996146 · Cited by 457
Self-citationLeón, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection
Singh, M., Kaur, M., Kukreja, H., Chugh, R., Silakari, O., & Singh, D. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.050 · Cited by 364
Multi-Target Drugs: The Trend of Drug Research and Development
Lu, J.-J., Pan, W., Hu, Y.-J., & Wang, Y.-T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040262 · Cited by 259
Metadata
- Authors
- Bolognesi, M. L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., & Melchiorre, C.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-11-30
- Volume
- 50
- Issue
- 26
- Pages
- 6446-6449
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2046159507
- Cited by
- 260
- References
- 29
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.